Generic Name: crizotinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Xalkori is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) or ROS1 positive.

General Info

Xalkori interferes with ALK, ROS1 and other receptor tyrosine kinases that play a role in cancer cell growth.

The PROFILE clinical trials showed that Xalkori improved response rates and delayed disease progression compared with chemotherapy in people with metastatic ALK-positive NSLC. The response rate was 66% in patients with metastatic ROS1-positive NSCLC. Xalkori was approved in 2011.


Dosing Info:

Xalkori is taken as a capsule once daily, or twice daily in those with serious liver or kidney problems.

Side Effects

Common adverse events include vision problems, nausea, vomiting, diarrhea, constipation, swelling, fatigue, decreased appetite, dizziness, neuropathy and elevated liver enzymes. More serious side effects may include severe liver toxicity, lung inflammation, heart rhythm abnormalities and severe vision loss. Xalkori can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 22, 2019